Breakthrough Therapy Designation for ocrelizumab in PPMS
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation for Roche’s investigational medicine ocrelizumab (Ocrevus) for the treatment of people with primary progressive multiple sclerosis (PPMS).
Click on this link for more information.
